Mechanisms of calcification in Fahr disease and exposure of potential therapeutic targets
Publication date
2020-10
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Purpose of review: There is growing interest in disorders involved in ectopic mineralization. Fahr disease or idiopathic basal ganglia calcification can serve as a model for ectopic mineralization in the basal ganglia, which is fairly common in the general population. In this review, we will focus on causative gene mutations and corresponding pathophysiologic pathways in Fahr disease. Recent findings: Patients with Fahr disease have a variability of symptoms, such as movement disorders, psychiatric signs, and cognitive impairment, but can also be asymptomatic. Fahr disease is mostly autosomal dominant inherited, and there are mutations found in 4 causative genes. Mutations in SLC20A2 and XPR1 lead to a disrupted phosphate metabolism involving brain-specific inorganic phosphate transporters. Mutations in PDGFB and PDGFRB are associated with disrupted blood-brain barrier integrity and dysfunctional pericyte maintenance. In addition, the MYORG gene has recently been discovered to be involved in the autosomal recessive inheritance of Fahr. Summary: Knowledge about the mutations and corresponding pathways may expose therapeutic opportunities for patients with Fahr disease and vascular calcifications in the brain in general.
Keywords
Taverne, Clinical Neurology, Journal Article, Review
Citation
Peters, M E M, de Brouwer, E J M, Bartstra, J W, Mali, W P T M, Koek, H L, Rozemuller, A J M, Baas, A F & de Jong, P A 2020, 'Mechanisms of calcification in Fahr disease and exposure of potential therapeutic targets', Neurology: Clinical Practice, vol. 10, no. 5, pp. 449-457. https://doi.org/10.1212/CPJ.0000000000000782